TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned an average rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $122.70.

TMDX has been the topic of several analyst reports. Robert W. Baird cut their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. TD Cowen reduced their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th.

Insiders Place Their Bets

In related news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now owns 732 shares in the company, valued at $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at approximately $3,089,766.32. This trade represents a 12.43 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 19,417 shares of company stock valued at $2,240,738. 7.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently added to or reduced their stakes in TMDX. Driehaus Capital Management LLC lifted its holdings in shares of TransMedics Group by 15.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after buying an additional 202,867 shares during the period. Principal Financial Group Inc. lifted its holdings in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after acquiring an additional 146,115 shares during the period. Hood River Capital Management LLC purchased a new stake in TransMedics Group in the 2nd quarter worth approximately $18,854,000. Canada Pension Plan Investment Board acquired a new stake in shares of TransMedics Group during the 2nd quarter worth approximately $16,086,000. Finally, F M Investments LLC acquired a new position in shares of TransMedics Group in the 2nd quarter valued at $10,957,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Trading Up 1.5 %

NASDAQ TMDX opened at $62.65 on Tuesday. TransMedics Group has a one year low of $59.72 and a one year high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of 66.65 and a beta of 2.06. The company’s 50-day simple moving average is $88.42 and its two-hundred day simple moving average is $128.74.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business’s quarterly revenue was up 63.7% on a year-over-year basis. During the same period last year, the firm earned ($0.12) EPS. Equities analysts forecast that TransMedics Group will post 1 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.